NCT00233870View on ClinicalTrials.gov

A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.

CompletedOBSERVATIONAL
Enrollment

405

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Fabry Disease
Interventions
DRUG

Agalsidase beta (recombinant form)

agalsidase beta 1.0 mg/kg body weight infused every 2 weeks as an intravenous infusion

Trial Locations (1)

980-8574

Tohoku University Hospital, Sendai

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00233870 - A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease. | Biotech Hunter | Biotech Hunter